Relationship of genital wart burden to therapeutic response to fluorouracil/epinephrine injectable gel.
The efficacy of a single cycle of a new therapy for genital warts, intradermal fluorouracil/epinephrine (5-FU/epi) injectable gel, has been evaluated in 2 large pivotal trials; the objective of this study was to evaluate a second cycle of treatment. Twenty-two patients with total wart areas of 5-447 mm2 were treated with up to 2 cycles of < or =6 treatments of 5-FU/epi gel. After the first cycle of treatments, patients with warts showing a partial response or no response or new warts were continued into a second cycle. Seventy-three per cent (16/22) of patients had complete responses. Patients with total wart areas < or = 100 mm2 tended to respond completely in the first cycle of treatment (average 4.7 treatments). Patients with numerous warts or large total wart areas (>100 mm2) required an average of 7.5 treatments to achieve a complete response. Thus, a second treatment cycle may be appropriate for difficult-to-treat patients with numerous warts or large total wart areas.
Swinehart
J M
JM
Colorado Medical Research Center, Denver 80210, USA.
Korey
A
A
Orenberg
E K
EK
D001830:Body Surface Area; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000473:pathology*; D004359:Drug Therapy, Combination; D004837:Epinephrine / Q000627:therapeutic use*; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005782:Gels; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007271:Injections, Intradermal; D015552:Injections, Intralesional; D008297:Male; D012008:Recurrence; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D005782:Gels; D007166:Immunosuppressive Agents; D014662:Vasoconstrictor Agents; D005472:Fluorouracil; D004837:Epinephrine